Clinical Trials › NCT05605782
Active, Not Recruiting
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
Sponsored by Bristol-Myers Squibb
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 9000
Target enrollment
1
U.S. states
Sep 2021
Start date
Jul 2033
Expected completion
Conditions studied
Multiple Sclerosis, Relapsing-Remitting
Where this trial is running (1 site)
Maryland1 site
Bethesda
MS centers in Maryland
Compare treatment centers near a trial site by center type, providers and trials.
View Maryland centers